Ubaid-Girioli Samira, Ferreira-Melo Sílvia Elaine, Souza Leoní Adriana, Nogueira Eduardo Arantes, Yugar-Toledo Juan Carlos, Coca Antonio, Moreno Heitor
Laboratory of Cardiovascular Pharmacology and Hypertension, Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil.
J Clin Hypertens (Greenwich). 2007 Oct;9(10):770-4. doi: 10.1111/j.1751-7176.2007.tb00091.x.
Renin-angiotensin-aldosterone system (RAAS) hyperactivity is implicated in the development of hypertension and progressive damage in target organs. Chronic inhibition of the RAAS or use of thiazide-type diuretics may trigger an aldoster-one escape. The aim of this study was to assess this phenomenon in hypertensive patients treated with thiazide-type diuretics (hydrochlorothiazide [HCTZ]) or single or double blockade of the RAAS (irbesartan [IRBE], quinapril [QUIN], and IRBE+QUIN). Blood pressure levels were obtained by 24-hour ambulatory blood pressure monitoring. Plasma renin activity and aldosterone levels were determined by immunoradiometric assay. Blood pressure level was normalized in the 4 treatment groups; the HCTZ and IRBE+QUIN groups showed an increased plasma aldosterone level after 12 weeks (9.1+/-2.2 to 14.1+/-1.4 and 6.9+/-1.9 to 12.9+/-2.3 ng/dL, respectively; P<.05), whereas plasma renin activity was increased only in the HCTZ group (0.9+/-0.2-1.7+/-0.2 ng/mL/h; P<.05). The increase in plasma aldosterone level after 12 weeks of HCTZ and IRBE+QUIN therapy suggests early aldosterone escape.
肾素-血管紧张素-醛固酮系统(RAAS)功能亢进与高血压的发生及靶器官的进行性损害有关。长期抑制RAAS或使用噻嗪类利尿剂可能引发醛固酮逃逸现象。本研究旨在评估接受噻嗪类利尿剂(氢氯噻嗪[HCTZ])或RAAS单重或双重阻断治疗(厄贝沙坦[IRBE]、喹那普利[QUIN]以及IRBE + QUIN)的高血压患者中的这一现象。通过24小时动态血压监测获取血压水平。采用免疫放射分析法测定血浆肾素活性和醛固酮水平。4个治疗组的血压水平均恢复正常;HCTZ组和IRBE + QUIN组在12周后血浆醛固酮水平升高(分别从9.1±2.2升高至14.1±1.4以及从6.9±1.9升高至12.9±2.3 ng/dL;P<0.05),而仅HCTZ组的血浆肾素活性升高(从0.9±0.2升高至1.7±0.2 ng/mL/h;P<0.05)。HCTZ和IRBE + QUIN治疗12周后血浆醛固酮水平的升高提示早期醛固酮逃逸。